BioNTech (NASDAQ:BNTX) CEO Sells 33,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 33,000 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00. Following the completion of the sale, the chief executive officer owned 456,209 shares of the company’s stock, valued at approximately $44,621,802.29. The trade was a 6.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.

BioNTech Stock Up 2.9%

Shares of BNTX traded up $2.87 during mid-day trading on Tuesday, reaching $100.87. The company had a trading volume of 1,050,346 shares, compared to its average volume of 1,100,679. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a market capitalization of $25.51 billion, a price-to-earnings ratio of -12.88 and a beta of 1.29. The firm has a 50-day moving average price of $97.54 and a 200 day moving average price of $94.82. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.60) earnings per share. On average, sell-side analysts forecast that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Engineers Gate Manager LP grew its holdings in BioNTech by 17.3% during the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after buying an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech during the 2nd quarter valued at approximately $39,000. Nykredit A S purchased a new position in shares of BioNTech in the second quarter valued at $293,000. B. Metzler seel. Sohn & Co. AG grew its holdings in shares of BioNTech by 66.7% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after purchasing an additional 4,390 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in BioNTech in the second quarter worth $2,520,000. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

BNTX has been the topic of a number of research reports. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Berenberg Bank set a $140.00 price target on shares of BioNTech in a research report on Wednesday, September 16th. Canaccord Genuity Group dropped their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Finally, Citigroup cut their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.